Exscientia’s Post

Discover the power of #AI in #drugdiscovery: faster candidate identification, reduced lab costs, and accelerated timelines, all made possible by advanced computing solutions with Amgen and Terray Therapeutics. https://bit.ly/3YkRUXE

Discover the power of #AI in #drugdiscovery: faster candidate identification, reduced lab costs, and accelerated timelines, all made possible by advanced computing solutions with Amgen and Terray Therapeutics. https://bit.ly/3SsRU3Y

"Drug development teams have found significant data and modeling challenges in regard to tackling the complexities associated with #PDIinhibitors given the challenges with creating meaningful models, and accumulating and deciphering the data," said Panna Sharma, CEO and President of Lantern Pharma. "Our #AI platform, RADR®, can increase the confidence, insights, and comfort levels in developing data-driven development paths by modeling highly complex scenarios at a scale that only has become possible recently. It’s an ideal approach for Oregon Therapeutics, which has executed a series of highly targeted in vivo and in vitro experiments and is poised to make incredibly important and patient-centric decisions about the clinical future of the molecule. That's where RADR® can play a highly essential and market defining role." https://lnkd.in/g8XPQSsa #biotech #businessdevelopment #artificialintelligence

Discover the power of #AI in #drugdiscovery: faster candidate identification, reduced lab costs, and accelerated timelines, all made possible by advanced computing solutions with Amgen and Terray Therapeutics. https://bit.ly/4d0ps1I

The comprehensive AI drug discovery report we've been waiting for. This new report from Andrii Buvailo, Ph.D. in BioPharmaTrend.com offers an in-depth look at the timeline and pipeline trajectory of all the major players in AI drug discovery -- and will serve as a valuable ongoing resource. It includes the initial emergence of AI drug discovery startups in 2012, the first validated AI-designed molecules from Insilico Medicine in 2019, up-to-date pipelines for companies advancing AI-designed drugs into clinical trials, and the consolidations and inroads by big tech happening across the industry. Highly recommend bookmarking this one! *Link to full report in comments. #ai #drugdiscovery #biotech #pharma #techbio #industry #pipeline

How AI Will Impact the Drug Discovery Pipeline-“The most progressive players in #drugdiscovery are accelerating toward an #AI-enabled, #multimodal drug discovery future” #EnterpriseAI

💲 SOM Biotech Announces the Closure of an Internal Round for €5.5m SOM Biotech, a clinical-stage drug discovery and development company based on a unique proprietary artificial intelligence (AI) platform, announces the closure of an internal round for €5.5m to secure the completion of the Phase IIb study on Huntington patients with its lead candidate SOM3355. Read fresh #pressrelease in comment section! #clinicaltrials #funding #artificialintelligence #clinicalstudies #drugdiscovery

The pharma industry is at the cusp of a revolution with AI-powered in-silico drug discovery! This method isn't just a game-changer—it's a lifeline for rapid, cost-effective, and accurate drug development. Surprisingly, even Mars is leading with patents! Such innovation is critical for addressing urgent health challenges. Dive into this transformative journey and how it's reshaping our approach to therapies. Thoughts on this AI-driven future? #InSilico #DrugDiscovery #AI #PharmaInnovation Join the conversation! Original article: https://lnkd.in/eSKX7ttZ

As part of #slas2024, I shared some thoughts on the #datascience and #aiml program track with Drug Discovery World. https://lnkd.in/eWn8-d_V

Recursion and Exscientia are merging is one of the first major M&A events in the AI drug development field. What do you think of the deal? Was Exscientia a good acquisition target? #biotech #AI #artificialintelligence #machinelearning #generativebiology #mergersandacquisitions #computationalbiology